- Home
- PRTG vs OGEN Comparison
PRTG vs OGEN Comparison
Compare PRTG & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTG
- OGEN
- Stock Information
- Founded
- PRTG 1973
- OGEN 1996
- Country
- PRTG British Virgin Islands
- OGEN United States
- Employees
- PRTG N/A
- OGEN N/A
- Industry
- PRTG Oil & Gas Production
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- PRTG Energy
- OGEN Health Care
- Exchange
- PRTG Nasdaq
- OGEN Nasdaq
- Market Cap
- PRTG 4.7M
- OGEN 4.5M
- IPO Year
- PRTG N/A
- OGEN N/A
- Fundamental
- Price
- PRTG $4.69
- OGEN $0.28
- Analyst Decision
- PRTG Hold
- OGEN
- Analyst Count
- PRTG 1
- OGEN 0
- Target Price
- PRTG N/A
- OGEN N/A
- AVG Volume (30 Days)
- PRTG 40.3K
- OGEN 635.1K
- Earning Date
- PRTG 12-03-2024
- OGEN 11-13-2024
- Dividend Yield
- PRTG N/A
- OGEN N/A
- EPS Growth
- PRTG N/A
- OGEN N/A
- EPS
- PRTG N/A
- OGEN N/A
- Revenue
- PRTG N/A
- OGEN N/A
- Revenue This Year
- PRTG N/A
- OGEN N/A
- Revenue Next Year
- PRTG N/A
- OGEN N/A
- P/E Ratio
- PRTG N/A
- OGEN N/A
- Revenue Growth
- PRTG N/A
- OGEN N/A
- 52 Week Low
- PRTG $2.10
- OGEN $0.25
- 52 Week High
- PRTG $40.80
- OGEN $7.74
- Technical
- Relative Strength Index (RSI)
- PRTG 46.17
- OGEN 38.50
- Support Level
- PRTG $3.81
- OGEN $0.25
- Resistance Level
- PRTG $4.78
- OGEN $0.43
- Average True Range (ATR)
- PRTG 0.56
- OGEN 0.04
- MACD
- PRTG 0.04
- OGEN 0.00
- Stochastic Oscillator
- PRTG 56.33
- OGEN 17.78
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.